Research Article

Uncaria tomentosa for Reducing Side Effects Caused by Chemotherapy in CRC Patients: Clinical Trial

Table 2

Evaluation of hemoglobin, and erythrocyte indices of the CRC patients, during six cycles of adjuvant/palliative chemotherapy, without Uncaria tomentosa supply (C group) or receiving 300 mg/day of Uncaria tomentosa (UT group).

ParametersGroupChemotherapy cycle
0123456

HbUT123.5125.2127.2123.5125.3121.4118.6
g/L(14.9)(17.9)(17.0)(14.2)(13.9)(11.1)(10.4)
C113.7115.1113.3113.9114.9117.0113.7
(17.6)(13.8)(15.7)(17.2)(14.2)(12.5)(14.2)
MCHUT27.5327.8828.3728.9529.6629.6930.60*
pg(1.99)(1.69)(1.97)(2.20)(2.31)(1.92)(2.16)
C26.6227.0227.3727.7027.9328.8029.19*
(2.61)(2.63)(2.59)(2.67)(2.63)(2.60)(2.44)
MCVUT84.6285.3186.0387.5789.1390.0091.50**
fL(4.31)(3.91)(3.65)(5.36)(5.59)(4.90)(4.84)
C81.9482.5383.7485.2886.2788.2989.22**
(6.8)(6.58)(6.4)(6.34)(6.02)(5.92)(5.51)

Values expressed as mean (SD). Hb: hemoglobin, MCH: mean corpuscular hemoglobin, MCV: mean corpuscular volume. UT group: patients treated with FOLFOX4 + Uncaria tomentosa 300 mg/day ( ), C group: patients treated with FOLFOX4 ( ); * ; ** ; *** in relation to the day 0.